Talk:Blood lancet

Proposed expansion of this article

This article is currently a stub and is missing significant information about the types, regulation, and clinical use of blood lancets. I'd like to suggest the following additions, all of which are well-sourced from government and regulatory publications. I have a potential conflict of interest related to this topic, so I'm proposing these changes here for independent editors to review and implement per [WP:COI](https://en.wikipedia.org/wiki/Wikipedia:Conflict_of_interest) guidelines.

Proposed Section: Types of Blood Lancets

The current article does not distinguish between the major categories of lancets recognized by the FDA. A "Types" section could cover:

• Single-use lancets with integral sharps injury prevention feature — Disposable lancets with a built-in safety mechanism that automatically retracts or shields the blade after a single use, rendering the device permanently inoperable. These are classified as FDA Class II devices under 21 CFR 878.4850(a).

• Single-use lancets without sharps injury prevention — Traditional twist-top or snap-off lancets intended for one-time use but lacking an automatic disabling mechanism. Also classified as FDA Class II under 21 CFR 878.4850(b).

• Multiple-use lancets for single patient use — Devices with a reusable base that accepts replaceable blades, intended for repeated use by a single patient only (e.g., spring-loaded lancing devices used in home glucose monitoring). FDA Class II under 21 CFR 878.4850(c).

• Multiple-use lancets for multiple patient use — Devices historically cleared for use on more than one patient, now recognized by the FDA as posing unacceptable risk of bloodborne pathogen transmission. Reclassified to FDA Class III (requiring premarket approval) in 2021.

Sources:

• 21 CFR § 878.4850 — Blood lancets (https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-878/subpart-E/section-878.4850)
• Federal Register, Nov 22, 2021: "Medical Devices; General and Plastic Surgery Devices; Reclassification of Blood Lancets" (https://www.federalregister.gov/documents/2021/11/22/2021-25376/medical-devices-general-and-plastic-surgery-devices-reclassification-of-blood-lancets)

Proposed Section: Gauge Sizes

The article does not mention gauge sizes, which are central to how patients and clinicians select lancets. A brief section could note:

• Lancet needle thickness is measured in gauge (G), where a higher number indicates a thinner needle.
• Common gauges range from 21G to 33G. The most widely used sizes for home blood glucose monitoring are 28G, 30G, and 33G.
• Thinner gauges (30G–33G) generally cause less pain but produce smaller blood samples. Thicker gauges (21G–28G) produce larger samples but may cause more discomfort.
• Many lancing devices allow adjustable penetration depth to accommodate different skin thicknesses.

Sources:

• FDA 510(k) clearance documents for blood lancets (multiple, available via accessdata.fda.gov)

Proposed Section: Regulation and Safety

This is the biggest gap. The article currently has no mention of the significant regulatory history around blood lancets:

• In 2010, the FDA and CDC issued a joint safety communication warning that using fingerstick devices on more than one patient poses a risk of transmitting bloodborne pathogens, particularly hepatitis B. The CDC had documented a progressive increase in nosocomial transmission cases linked to shared lancet use in healthcare settings.

• In November 2010, the FDA published "Guidance for Industry and FDA Staff: Blood Lancet Labeling," recommending that all blood lancets be labeled for single-patient use only.

• In 2013, the FDA's General and Plastic Surgery Devices Panel recommended reclassifying all blood lancets from Class I to Class II, finding that general controls alone were insufficient to ensure safety and effectiveness.

• In 2021, the FDA finalized a rule reclassifying blood lancets into three Class II categories (single-use with sharps protection, single-use without, and multi-use single-patient) and one Class III category (multi-use multi-patient), requiring 510(k) premarket notification for Class II devices and premarket approval for Class III.

• The Needlestick Safety and Prevention Act of 2000 (Pub. L. 106-430) required OSHA to update its Bloodborne Pathogens Standard, mandating that employers implement engineering controls including sharps with engineered injury protections. Blood lancets with safety features fall under this requirement in healthcare settings.

Sources:

• FDA Safety Communication: "Use of Fingerstick Devices on More Than One Person Poses Risk for Transmitting Bloodborne Pathogens" (2010, updated)
• Federal Register, Nov 29, 2010: Blood Lancet Labeling Guidance (https://www.federalregister.gov/documents/2010/11/29/2010-29795/guidance-for-industry-and-food-and-drug-administration-staff-blood-lancet-labeling-availability)
• Federal Register, Mar 3, 2016: Proposed Reclassification (https://www.federalregister.gov/documents/2016/03/03/2016-04578/general-and-plastic-surgery-devices-reclassification-of-blood-lancets)
• Federal Register, Nov 22, 2021: Final Reclassification Order (https://www.federalregister.gov/documents/2021/11/22/2021-25376/medical-devices-general-and-plastic-surgery-devices-reclassification-of-blood-lancets)
• OSHA Bloodborne Pathogens Quick Reference (https://www.osha.gov/bloodborne-pathogens/quick-reference)
• 29 CFR 1910.1030 — Bloodborne Pathogens Standard

Proposed Section: Proper Use and Disposal

A brief section on correct usage:

• Lancets are designed for single use. Reuse dulls the needle, increases pain, and raises infection risk.
• Used lancets should be disposed of in FDA-cleared sharps containers, not regular household trash.
• In healthcare settings, OSHA requires that contaminated sharps be discarded immediately into puncture-resistant containers located at the point of use.
• The FDA requires that lancet labeling include the warning: "Not intended for more than one use. Do not use on more than one patient."

Sources:

• 21 CFR § 878.4850
• OSHA 29 CFR 1910.1030(d)(4)(iii)
• FDA Blood Lancet Labeling Guidance (2010)

---

I'm happy to draft specific wikitext for any or all of these sections if editors find the proposed content appropriate. Rebeljp (talk) 16:33, 3 March 2026 (UTC)